Search Results
Results found for "David Reiner-Link"
- How a Failed Med School Dream Sparked a GPCR Biotech Revolution
Lessons From the Front Lines of Biotech Ajay’s experience in both early-stage biotech and academic science
- What's Going On with GPCRs?! Find Out in This Week's Update! ⦿ Nov 4 - 10, 2024
GPCR Events to keep you informed and engaged GPCR Jobs connecting candidates with positions Direct line
- From Lab Logic to Leadership: How Scientific Thinking Holds Back Biotech Operations
👉 Bottom line: Scientific thinking is invaluable, but only when it’s reframed for the role you’re
- 📰 GPCR Weekly News - January 9 to 15, 2023
Mechanism of Action and Target Engagement Novo Nordisk's GLP-1 for Type II diabetes approved for first-line
- GPCR Collaboration: From Models to Medicine
Biased signaling, allosteric binding sites, and subtype selectivity mean there is rarely a straight line
- 📰 GPCR Weekly News, September 4 to 10, 2023
Immunology [1,2,4]Triazolo[1,5-c]pyrimidines as Tools to Investigate A3 Adenosine Receptors in Cancer Cell Lines
- 📰 GPCR Weekly News, November 13 to 19, 2023
Study Completes Recruitment of Patients Sanyou Bio's Evolution of Bioprocess Enhancement for CHO Cell Lines
- Orthosteric Binding Experiments: How to Avoid the Most Common Data Pitfalls
✅ AMA replays + priority Q&A — Rewatch all 3 live AMAs and move your questions to the front of the line
- 📰 GPCR Weekly News, January 15 to 21, 2024
News Novartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line
- Exciting GPCR Events for Next Year! + GPCR Weekly Rocket Launch ⦿ Oct 28 - Nov 3, 2024
Exciting event listings to keep you on your toes Direct line to all the cool cats in the GPCR community
- High-Content Screening for GPCR Programs: Overcoming Assay Limitations with Fluorescent Ligands
CB 2 -expressing HEK cell lines are labeled with CELT-331 at 80 nM (right), while competition with the Lin S, Schorpp K, Rothenaigner I, Hadian K. Image-based high-content screening in drug discovery.
- A2A Fluorescent Competitive Binding: Advancing NanoBRET® Target Engagement for GPCR Drug Discovery
Then, the linker composition is optimized, by using different hinges and spacers . Celtarys’ technology significantly reduces the time it takes to obtain fluorescent tags and test varying linker tracers (CELT-463 and CELT-464) , bearing the same pharmacophore and fluorophore, but with different linkers
- New Tools, Smart Signals, and The Kenakin Brief
It emphasizes scaffold selection, linker optimization, and assay compatibility to enhance target binding
- Radioligands vs. Fluorescent Ligands: Binding Assays
Strategic placement of the linker in the pharmacophore and its optimization ensure access to the binding
- Pharmacologic Models
How the Mass Action Law underpins nearly every model Future of Receptor Theory: Linkage vs.
- Beyond the Probe: Scaling Innovation From the Bench to Product Launch
Their method allows researchers to explore different linker positions, tailor activity (agonist or antagonist
- Illuminating GPCR Research: FRET and BRET-Based Sensors Shed Light on Cellular Signaling
BERKY consists of a membrane linker, a BRET donor, an ER/K α-helix linker, a BRET acceptor, and an active
- 📰 GPCR Weekly News, April 15 to 21, 2024
United With or Without an Additional Transmembrane Sequence Indicate Classification into Three Groups of Linkers
- Endothelin-1 Stimulates PAI-1 Protein Expression via Dual Transactivation Pathway Dependent ROCK...
Smad2L "In addition to the carboxy region, Smad2 transcription factor can be phosphorylated in the linker Phosphorylation of Smad2 linker region (Smad2L) promotes the expression of plasminogen activator inhibitor were investigated<br />by western blotting using protein-specific antibodies against phospho-Smad2 linker













